Proof-of-concept: SCENTinel 1.1 rapidly

discriminates COVID-19 related olfactory

3 disorders

4

8

12

13

15

21

- 5 Stephanie R. Hunter^{1†}, Mackenzie E. Hannum^{1†}, Robert
- 6 Pellegrino¹, Maureen A. O'Leary¹, Nancy E. Rawson¹, Danielle
- 7 R. Reed¹, Pamela H. Dalton¹, Valentina Parma^{1,2*}
- 9 ¹ Monell Chemical Senses Center, Philadelphia, PA
- 10 ² Department of Psychology, Temple University, Philadelphia, PA
- 11 † Equal contributions
- 14 *Correspondence:
- 16 Valentina Parma, PhD
- 17 Monell Chemical Senses Center
- 18 3500 Market Street
- 19 Philadelphia, PA 19143
- 20 Email: <u>vparma@monell.org</u>
- 22 **Keywords:** Anosmia, hyposmia, parosmia, phantosmia, prediction, smell test

Abstract

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

It is estimated that 20-67% of those with COVID-19 develop olfactory disorders, depending on the SARS-CoV-2 variant. However, there is an absence of quick, population-wide olfactory tests to screen for olfactory disorders. The purpose of this study was to provide a proof-of-concept that SCENTinel 1.1, a rapid, inexpensive, population-wide olfactory test, can discriminate between anosmia (total smell loss), hyposmia (reduced sense of smell), parosmia (distorted odor perception), and phantosmia (odor sensation without a source). Participants were mailed a SCENTinel 1.1 test, which measures odor detection, intensity, identification, and pleasantness, using one of four possible odors. Those who completed the test (N = 381) were divided into groups based on their self-reported olfactory function: quantitative olfactory disorder (anosmia or hyposmia, N = 135), qualitative olfactory disorder (parosmia and/or phantosmia; N = 86), and normosmia (normal sense of smell; N = 66). SCENTinel 1.1 accurately discriminates quantitative olfactory disorders, qualitative olfactory disorders, and normosmia groups. When olfactory disorders were assessed individually, SCENTinel 1.1 discriminates between hyposmia, parosmia and anosmia. Participants with parosmia rated common odors less pleasant than those without parosmia. We provide proof-of-concept that SCENTinel 1.1, a rapid smell test, can discriminate quantitative and qualitative olfactory disorders, and is the only direct test to rapidly discriminate parosmia.

Introduction

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Prior to March 2020, a nationally representative survey in 3,603 individuals reported more than 20% of individuals experienced olfactory disorders over the course of their lifetime [1]. These olfactory disorders, broadly classified, include quantitative and qualitative olfactory disorders, which can occur in isolation or together [2,3]. Quantitative olfactory disorders are those where the perceived intensity of the odor is diminished and include anosmia (e.g., total smell loss) and hyposmia (e.g., reduced sense of smell). Qualitative olfactory disorders are disorders where the perceived quality or identity of an odor is changed, including parosmia (e.g., distorted odor perception with a known source) and phantosmia (e.g., odor sensation without an odor source). These olfactory disorders have a large negative impact on overall quality of life [4]. The prevalence of quantitative olfactory disorders has increased dramatically due to the COVID-19 pandemic, where sudden loss of smell is a specific symptom [5]. As of June 2022, there have been more than 86 million reported cases of COVID-19 in the United States alone [6]. Of those who contract COVID-19, about 50% self-report losing their sense of smell [7]. While most of these individuals fully recover their sense of smell within three weeks [8–11], about 10-15% have persistent smell loss for more than one month [8,12]. Thus, millions of Americans are now at risk of experiencing chronic smell loss due to COVID-19. These prevalence estimates of smell loss from COVID-19 remain uncertain, however, because of symptomatic differences in SARS-CoV-2 variants (e.g., smell loss is not as prevalent with the omicron variant compared to the previous variants) [7,13,14]. Furthermore, people are generally not proficient at subjectively assessing their smell ability [1,7,15–18]. Prior research has shown that directly testing olfactory function provides a better representation of the prevalence of smell loss compared to self-report

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

[7]. Currently validated smell tests, such as UPSIT [16,19–24], Sniffin' Sticks [25–27], or the NIH Toolbox Odor Identification Test [28], among others, are sensitive at accurately identifying quantitative olfactory disorders, including anosmia and hyposmia. However, these tests lack suitability for population-wide surveillance of smell function, especially during the COVID-19 pandemic, due to their odor delivery method, increased cost and time to execute, and/or because the test cannot be self-administered. To address these shortcomings in olfactory testing, we created the SCENTinel Rapid Smell Test [29]. The first version of the test, SCENTinel 1.0, is a self-administered test that uses flower as a target odor to assess odor detection ("select the patch with the strongest odor"), odor intensity ("rate the intensity of the odor" using a visual analog scale from 1–100), and odor identification ("identify the odor" when given four picture/label options). To enable the use of SCENTinel as a rapid test of smell function, accuracy criteria were established: odor detection and odor identification answers are coded as correct or incorrect and odor intensity uses a cutoff of 20 to determine normal smell function (i.e., normosmia), based on a previous study by Gerkin et al [5]. These three subtests are then combined to create an overall score, which was previously found to differentiate between people self-reporting anosmia from normosmia [29]. Many of the direct approaches to assess olfactory function only focus on quantitative smell disorders and there remains a dearth of direct tests that discriminate for qualitative olfactory disorders, including parosmia and phantosmia. Often, qualitative olfactory disorders are diagnosed through subjective ratings from questionnaires and/or patient history obtained through interviews [30–35]. This reliance on self-report leaves estimates of qualitative olfactory disorders likely underrepresented, only diagnosed when individuals consult specialists. However, even with subjective reports, qualitative olfactory disorders are present in more than half of those

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

reporting smell impairment [36–38], and distinct features of parosmia and phantosmia are beginning to surface [31]. Parosmia encompasses distortions of a known odor, often experiencing pleasant odors as unpleasant or vice versa [39], so one way to assess parosmia directly is to have participants rate the pleasantness of two oppositely valenced odors (i.e., a pleasant and unpleasant odor). This procedure creates a hedonic score, such that those with parosmia have a lower hedonic score than those with normosmia, assuming those with parosmia would rate the pleasant odor as unpleasant. Liu and colleagues successfully employed this technique to classify two patients with parosmia [27]. Directly testing for parosmia may still prove difficult, because parosmia reports are not consistent across all odors. Odors that are frequently associated with parosmia include coffee, meats, onion, garlic, and chocolate [2,31,40], yet the direct cause for the odor-specificity remains to be understood. Individuals with odorspecific parosmia may only be detected with direct smell tests if the distorted odor is used in the test, and therefore, multiple odor versions are needed. Overall, there is a pressing need to directly measure quantitative and qualitative olfactory disorders in a fast and inexpensive way to enable a better assessment of the magnitude of smell impairments in the population. Once validated against gold-standards and normed, such tests may help to diagnose diseases where smell loss is a symptom (including head trauma [41–43], neurodegenerative diseases [44–46], and viral illness [47]), and help evaluate the impact of treatments and therapies for those living with olfactory disorders. Here, we extend SCENTinel 1.0 to a new version, SCENTinel 1.1, with the goal to discriminate between quantitative and qualitative olfactory disorders. Using the rationale from Liu et al. [27], we include a hedonic score subtest to discriminate qualitative olfactory disorders population-wide. Specifically, after participants complete the odor detection, intensity, and

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

identification subtests, they will rate the pleasantness of two oppositely valenced odors (the actual odor on the SCENTinel test received, and an imagined, universally unpleasant odor) to create a hedonic score to directly measure parosmia and phantosmia. Using two odors enables a common anchor between the hedonic scores to account for varying scale usage. Additionally, SCENTinel 1.1 includes four target odor versions: flower (the same odor in SCENTinel 1.0), bubblegum, coffee, and caramel popcorn (Supplementary Table S1), enabling SCENTinel to be used for repeat testing (12 different odor/placement combinations) and to capture potential odorspecific olfactory symptoms. In the present study, we sought to test the ability of SCENTinel 1.1 to discriminate different smell disorders through three aims. First, we aim to validate the ability of SCENTinel 1.1 (with multiple target odors) to discriminate between those with normosmia and anosmia, based on the original model developed with SCENTinel 1.0 (with one target odor) [29]. We hypothesize that SCENTinel 1.1 will discriminate between participants with normosmia and anosmia similarly to that reported in SCENTinel 1.0. Second, we aim to determine SCENTinel 1.1's accuracy in distinguishing between quantitative (anosmia and hyposmia) and qualitative (parosmia and phantosmia) olfactory disorders. Specifically, we expect those with quantitative olfactory disorders will rate the odor intensity as low or absent and may not be able to distinguish the odor stimulus, therefore unable to meet the accuracy criteria for odor detection, intensity and, likely, identification if they are anosmic or severely hyposmic. Those with qualitative olfactory disorders may correctly detect the odor and rate the intensity >20, but its quality may be distorted, so we hypothesized that they would perform better overall on SCENTinel 1.1 compared to those with quantitative disorders, but their odor identification ability might be jeopardized.

Finally, we aim to explore whether assessing odor pleasantness can accurately discriminate those with parosmia. Experiencing distorted odors is often reported as an unpleasant experience [39], therefore we hypothesized that those with qualitative olfactory disorders (i.e., parosmia) would report a lower hedonic score for common odorants included in SCENTinel 1.1 than those without distortion (e.g., people with hyposmia or normosmia).

Materials & Methods

The materials, procedures, hypotheses, and pre-analysis plan were pre-registered and are publicly available in the Open Science Framework Repository [48].

SCENTinel 1.1

The SCENTinel 1.1 test card contains three patches created with Lift'nSmell technology (Scentisphere, Carmel, NY), of which only one patch contains a target odor and the other two are blank. SCENTinel 1.1 includes four subtests: odor detection accuracy (correct/incorrect); odor intensity (above/below a cutoff of 20, or continuous value depending on the analysis); odor identification among 4 given options (correct/incorrect) or, if the first response is incorrect, among the 3 remaining options (correct/incorrect); and a hedonic score (pleasantness rating of an unpleasant imagined odor (vomit) – pleasantness rating of the target odor on the SCENTinel test; procedure outlined in Supplementary Fig. S1). The target odor on SCENTinel 1.1 is one of four possible odors, such that participants received a SCENTinel 1.1 test with either a flower, a coffee, a bubblegum, or a caramel popcorn target odor. However, note that there is only one odor on each SCENTinel test. Therefore, participants smelled only one of the four possible odors. All odors were from Givaudan (Cincinnati, OH; see Supplementary Table S1 for catalog numbers)

and were designed to be iso-intense at an intensity of 80 on a scale of 0 to 100, confirmed via pilot testing.

Participants

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

Participants were recruited through two exclusive Facebook groups ("Covid-19 Smell and Taste Loss" and "AbScent Parosmia and Phantosmia Support" hosted by AbScent, a charity serving individuals with smell and taste disorders based in the UK), which were open to those suffering from olfactory disorders due to COVID-19 and their family and friends. Interested participants were instructed to complete an online survey to determine eligibility. Those who reside in the United States, between 18-75 years old, and have access to a smart device or computer were eligible for this study. Of the 1290 individuals who completed the eligibility survey, 733 were eligible and were mailed a SCENTinel 1.1 test on a first-come, first-served basis, and 512 participants completed the test (response rate: 70%; see Figure 4 for a schematic overview). Participants were excluded if they reported smell loss unrelated to COVID-19 (N = 19), illogical self-reported olfactory disorders (e.g., selected both anosmia and hyposmia or anosmia and parosmia; N = 30), selfreported full recovery at the time of the SCENTinel test (N = 2), a negative COVID-19 test (i.e., no confirmed COVID-19 diagnosis; N = 57), undiagnosed smell loss (i.e., reported having a current olfactory disorder other than anosmia, hyposmia, parosmia, or phantosmia; N = 11), or incomplete data (N = 12). Ultimately, 348 participants with a smell disorder from laboratoryconfirmed COVID-19 and 33 participants with normosmia were included in the final analyses. Participants were assigned to smell groups based on their response to the question outlined in Figure 4: 135 participants had only anosmia or hyposmia (quantitative olfactory disorder,

referred to as quantitative OD group), 86 had only parosmia or phantosmia (qualitative

olfactory disorder, referred to as **qualitative OD group**), and 94 reported having both quantitative and qualitative olfactory disorders (mixed), and 33 participants indicated that they did not have any issues with their sense of smell (normosmia). Because there was only a small population with normosmia in the Facebook groups, as expected given the nature of the group, we added a convenience sample of 33 participants with normosmia who met the inclusion criteria for this study. These additional participants completed SCENTinel 1.1 for a separate study, recruited via fliers around the Philadelphia, PA area. The separate and current studies are both part of the same, multi-site, IRB protocol, which was approved by the University of Pennsylvania Institutional Review Board (protocol no. 844425) and complied with the Declaration of Helsinki.

Odor placement and target odor were equally distributed among groups in participants who were included in the final analyses (Supplementary Table S5).

Procedure

Eligible participants received one SCENTinel 1.1 test, containing one of the four potential odors. Upon receiving the SCENTinel 1.1 test, participants scanned a QR code or entered a URL into a web browser that brought them to a REDCap survey [49]. Participants first provided consent using the approved online consent form. They then answered demographic information (age, gender, race, and ethnicity) and indicated whether they had issues with their smell or taste at the time of taking the test. If they answered yes, they indicated in a check-all-that-apply question (Figure 4) whether they 1) cannot smell anything (anosmia), 2) can smell some odors but they are weaker than usual (hyposmia), 3) can smell strong odors but they smell differently than they typically smell (parosmia), 4) smell things that are not there, such as smoke when there is no fire (phantosmia), 5) other. Participants were then instructed to lift and smell

each patch on the SCENTinel 1.1 card, one at a time, from left to right, and 1) select which patch smells the strongest (odor detection), 2) rate how intense the odor was on a 100-point visual analog scale (odor intensity), and 3) identify the odor out of four possible options (odor identification). If they identified the odor incorrectly the first time, they were given a second chance (three alternative-forced choice paradigm). Binary responses (correct/incorrect) to these subtests (odor detection, odor intensity, and odor identification; note: odor intensity subtest had a cut off of 20 out of 100) were used to calculate participants' overall score specified in a previous publication [29]. Potential response strategies are outlined in Table 1. Participants then rated the pleasantness of the odor on the card and the pleasantness of the smell of vomit (by imagining the smell) using a 100-point visual analog scale anchored with "Very Unpleasant" at 0 and "Very Pleasant" at 100. These pleasantness ratings were used to calculate a hedonic score [from –100 to 100] by subtracting the rating of the pleasantness of the odor on the card and the rating of the pleasantness of imagined vomit. The hedonic score was not included in the SCENTinel 1.1 overall score. Participants also rated the frequency at which they experienced distorted or phantom odors in the past week using a 100-point visual analog scale from 0 - "Never" to 100 -"All the time". These questions were similar to those used to measure parosmia in Liu et al [27].

[INSERT TABLE 1 HERE]

Data Analysis

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

This cross-sectional design included the between-subject factor "smell function" group (quantitative OD, qualitative OD, normosmia; Figure 4) and the following within-subject factors: meeting the accuracy criteria within SCENTinel 1.1 subtests (odor detection, intensity, identification), overall score, as well as the new subtest, hedonic score. The intensity subtest had

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

a cut-off of 20 (out of 100) when calculating SCENTinel 1.1 overall score, but was analyzed as a continuous measure (0-100) in the Bayes analysis and prediction model (described below) to benefit from the full-scale variability of the ratings. In accordance with the preregistration [48], we originally included a "mixed" group in the between-subject factor smell ability (Figure 4), but this group showed no coherent pattern (similar to a recent study [31]) and was therefore removed from the main analysis (see Supplementary Table S6). Demographics included in the analyses were sex (male, female), race (white, non-white), and age (continuous). Due to the unequal distribution of data across categories, we binarized race as white and non-white, which included those who were American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific Islander, and other. The linear discriminant model (LDA), which discriminated those with anosmia from normosmia in SCENTinel 1.0 [29], was prospectively validated with SCENTinel 1.1 participant pool. Participants with anosmia (N = 51) and normosmia (N = 66) from SCENTinel 1.1 were predicted with the prior model features - demographic variables (gender, age, ethnicity) as well as the original SCENTinel 1.0 item scores (odor detection, intensity, identification). The receiver operating characteristic (ROC) area under the curve (AUC) was calculated for the prospective validation dataset (SCENTinel 1.1) and compared to the prediction from prior withheld dataset (20% of the SCENTinel 1.0 data in the previous paper (AUC = 0.95)) [29]. Machine learning classification algorithms were applied to predict the ability of SCENTinel 1.1 to discriminate quantitative OD, qualitative OD, and normosmia groups of individuals greater than chance. Data were preprocessed using the procedures in our previous publication [29]. Multiclass models using random forest, linear, and radial small vector machine, regularized linear regression (Elastic net), and linear discriminant analysis (LDA) were

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

optimized with their respective tuning parameters using cross-validation. Cross-validation (number = 10, repeat = 5) was performed on the training set (80% of the sample), and validation was completed on the remaining, withheld data (20%). The model that provided the best classification multi-class AUC on the withheld data was LDA, which we report and discuss in the text. To look at specific olfactory disorders within quantitative and qualitative OD groups, a separate LDA model was fit to predict those with parosmia, hyposmia, and anosmia. Cutoff values were calculated with Youden's Index [50] for SCENTinel subcomponents that significantly predicted normosmia from quantitative and qualitative olfactory disorders from the machine learning classification algorithm. Youden's Index has previously been used to determine cutoff values in olfactory tests for clinical populations [51]. A sequential Bayes factor design (SBFD) with maximal N, as suggested by Schönbrodt et al. [52] was used to compare group performance between individual subtests of SCENTinel 1.1. This SBFD design requires on average half the sample size compared with the optimal null hypothesis testing fixed-n design, with comparable error rates [52]. The desired grade of relative evidence for the alternative (H_1) versus the null (H_0) hypothesis is set at the following: $BF_{10} >$ 100 (extreme evidence), $100 > BF_{10} > 30$ (very strong evidence), $30 > BF_{10} > 10$ (strong evidence), $10 > BF_{10} > 3$ (substantial evidence), and $3 > BF_{10} > 1$ (anecdotal evidence). Based on a Cohen's d = 0.5, we have specified a minimum sample size per group of $N_0 = 43$. To assess the differences in accuracy among subtests, we have employed Bayesian and parametric tests for equality of proportions with or without continuity correction. Planned contrasts were additionally done among the broad smell groups (i.e., quantitative OD, qualitative OD, normosmia), and among individual specific groups within each broad group (i.e., anosmia, hyposmia, parosmia). Phantosmia was not included in the specific group assessment given the reduced number of

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

people with phantosmia, in line with the current prevalence estimates [31]. Results from the SBFD planned contrasts can be found in Supplementary Table S3. We conducted an exploratory analysis to further investigate the hedonic ratings among those with and without parosmia. Welch's two-sample t-test assessed differences in hedonic score across the individual smell groups (i.e., hyposmia, normosmia, parosmia). Participants were collapsed into two groups depending on their self-reports: parosmia and no parosmia. Pearson's product-moment correlation assessed the relationship between the reported frequency of parosmia events and the reported hedonic range for those with parosmia. A 2-way ANOVA (independent variables: odor and parosmia group; random variable: participants) was conducted to investigate if the hedonic score was different across the four odors used in SCENTinel 1.1. Lastly, Welch's two-sample t-test assessed the overall difference in the odor and vomit rating across parosmia groups. All statistical analyses were conducted in the R Environment for Statistical Computing [53]. Results SCENTinel 1.1 with the four target odor variations maintains accurate performance in anosmia discrimination. To assess the validity of the original model [29], and the impact of the features included in SCENTinel 1.1 (e.g., multiple odor versions), we prospectively verified the ability of the SCENTinel 1.0 classification model to predict the performance of individuals with anosmia and normosmia in a new sample of participants with COVID-19-related smell loss tested with

SCENTinel 1.1. In Parma et al. 2021, the SCENTinel 1.0 classification model accurately

predicted individuals with anosmia (N = 111) and normosmia (N = 154) with an area under the curve (AUC) of 0.95 [29], and this same model predicted individuals with anosmia (N = 51) and normosmia (N = 66) in the present sample with an AUC of 0.94 (Figure 1). In other words, the lack of statistical difference between the AUCs of the two tests prospectively validates the original classification model [29] and its ability to extend to olfactory performance related to COVID-19 etiology (current sample). Given that SCENTinel 1.1 includes four odor targets, as compared to one odor target in SCENTinel 1.0, we also assessed whether the different odor targets impacted the ability to identify those with normosmia. There were no significant differences in the average intensity ratings (Bayes Factor giving evidence of H_1 over H_0 (BF₁₀) = 0.19) or the overall score (BF₁₀ = 0.19) across the four target odor variations of SCENTinel 1.1 in individuals with normosmia. The consistency of results across the different study populations from SCENTinel 1.0 [29] and SCENTinel 1.1 (current sample) confirms that the features added to SCENTinel 1.1 (e.g., multiple target odors) still accurately discriminate for self-reported normosmia and anosmia.

[INSERT FIGURE 1 HERE]

SCENTinel 1.1 discriminates between self-reported normosmia, and quantitative and qualitative olfactory disorders.

Using a new machine learning classification model that incorporates the features of SCENTinel 1.1 (e.g., hedonic score subtest, multiple odor versions) and aims to predict additional smell disorder groups, the SCENTinel 1.1 overall score model accurately discriminates normosmia (N = 66) and quantitative OD (N = 135) groups (AUC = 0.84; Figure

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

2A), quantitative and qualitative OD (N = 86) groups (AUC = 0.76; Figure 2B) and normosmia and qualitative OD groups (AUC = 0.73; Figure 2C), all at rates significantly better than chance. The SCENTinel 1.1 subtest that best discriminated normosmia, quantitative OD, and qualitative OD groups differed depending on the group comparison. The only subtest that discriminated between quantitative and qualitative OD groups greater than chance was odor intensity (AUC = 0.73; Figure 2B), where the qualitative OD group rated the odor intensity higher (67.4 \pm 27.4; Supplementary Table S2) than the quantitative OD group (44.5 ± 30.0 ; Supplementary Table S2). Normosmia and quantitative OD groups were discriminated by odor intensity (AUC = 0.84) and odor identification (AUC = 0.76) subtests (Figure 2A). The odor identification (AUC = (0.73), hedonic score (AUC = (0.71)), and odor detection (AUC = (0.70)) subtests all discriminated normosmia and qualitative OD groups (Figure 2C). Accuracy rates for all SCENTinel 1.1 subtests for each group (i.e., normosmia, quantitative OD, and qualitative OD groups) can be found in Supplementary Table S2. [INSERT FIGURE 2 HERE] We then used significant findings from the machine learning classification models to determine SCENTinel 1.1 cutoff values for this sample based on Youden's Index [50, 51]. Youden's index is defined for all points of a ROC curve, and its maximum value may be used as a criterion for determining the optimal cut-off point [50]. From this sample, rating odor intensity equal to or lower than 56/100 and incorrectly identifying the odor classifies SCENTinel 1.1 performance as aligned with that of participants with a self-reported quantitative OD

(Supplementary Table S4). Similarly, incorrectly detecting and identifying the odor, and a

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

hedonic score equal to or lower than 20/100 classifies performance at SCENTinel 1.1 as aligned with that of participants with a self-reported qualitative OD (Supplementary Table S4). SCENTinel 1.1 discriminates between self-reported anosmia, hyposmia, parosmia and normosmia. Both quantitative and qualitative OD groups are inherently heterogeneous, and individual olfactory disorders within each group can result in different performance on the SCENTinel 1.1 subtests and overall score. For example, within the quantitative OD group, individuals can have a reduced sense of smell (hyposmia) or total smell loss (anosmia). Those with hyposmia are still likely to accurately detect and identify the odor in the SCENTinel 1.1 test, but report a lower odor intensity, whereas those with anosmia would likely not be able to accurately detect or identify an odor on SCENTinel 1.1 without guessing. Given these inherent differences, we determined how performance on SCENTinel 1.1 differentiated the three most common olfactory disorders in our sample: hyposmia (N = 84), anosmia (N = 51), and parosmia (N = 66). The SCENTinel 1.1 overall score accurately predicts group classification - discriminating hyposmia from parosmia (AUC = 0.89), anosmia from parosmia (AUC = 0.82), and hyposmia from anosmia (AUC = 0.78). Accuracy rates for all SCENTinel 1.1 subtests for participants with anosmia, hyposmia, and parosmia can be found in Supplementary Table S2. Self-reported parosmia as captured by SCENTinel 1.1. We only assessed differences in the hedonic score between those with hyposmia, normosmia, and parosmia. Participants with anosmia were not included in this analysis since rating the pleasantness of an odor by those who cannot perceive it is meaningless. Furthermore, our results

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

confirm that excluding participants with anosmia from this analysis did not significantly contribute to hedonic score differentiation (Supplementary Table S3). As expected, the hedonic score was lowest for those with parosmia compared to those with hyposmia (t = 3.42, p < 0.001) and normosmia (t = 2.06, p = 0.04; Figure 3A). There was no difference in hedonic score between those with hyposmia and normosmia (t = 0.48, p = 0.64). Among those who had parosmia, the majority of participants experienced odor distortions most of the time (Figure 3B). Indeed, hedonic score and parosmia frequency were negatively correlated (R = -0.21, p < 0.001), such that individuals who experienced parosmia more frequently had a lower hedonic score compared to those who experience parosmia less frequently (Figure 3B). Given that there was no difference in the hedonic score between those with hyposmia and normosmia, and to isolate the effects of parosmia, we combined those with hyposmia and normosmia into one group to compare the hedonic score between those with parosmia (N = 66) and those without parosmia (N = 150). Coffee is the only odor in SCENTinel 1.1 that is frequently reported to be distorted with parosmia [35,40]. Therefore, we assessed whether there was an effect of the odor used in SCENTinel 1.1 on the hedonic score. There was a significant group effect such that participants with parosmia had lower hedonic scores compared to those without parosmia ($F_{3.285} = 13.78$, p < 0.001), but this did not differ between the four odors used in SCENTinel 1.1 ($F_{3.285} = 0.05$, p =0.99; Figure 3C). Differences in the hedonic score were primarily driven by a lower pleasantness ratings of the odor in the SCENTinel 1.1 test in those with parosmia (t = 4.43, p < 0.001), as opposed to the imagined pleasantness rating of vomit which did not differ between those with and without parosmia (t = -0.57, p = 0.57; Figure 3D).

Discussion

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

Initially developed for population surveillance of smell loss associated with COVID-19, SCENTinel,, has been shown to have additional value as an accurate, rapid test that can discriminate the most common olfactory disorders. This proof-of-concept study used SCENTinel 1.1, an extended version of SCENTinel 1.0, to discriminate for self-reported quantitative (anosmia or hyposmia) and qualitative (parosmia and/or phantosmia) olfactory disorders. Using one of four odors, each SCENTinel 1.1 version measures odor detection, intensity, identification, and odor pleasantness. The goal of this study was to first validate the ability of SCENTinel 1.1 to discriminate between participants with normosmia and anosmia based on the original model developed with SCENTinel 1.0. The second goal of this study was to investigate whether SCENTinel 1.1 can distinguish between quantitative and qualitative olfactory disorders. The third goal of this study was to assess the ability of the hedonic score to discriminate parosmia. Overall, SCENTinel 1.1 can accurately discriminate between self-reported quantitative OD, qualitative OD, and normosmia groups. Participants were grouped based on a common trait of their self-reported olfactory disorder. Those experiencing diminished perceived odor intensity, like people with anosmia and hyposmia, were grouped as people with quantitative olfactory disorders. Those having distorted odor perceptions, like people with parosmia and phantosmia, were grouped as people with qualitative olfactory disorders. However, we noticed heterogeneity and complexity in SCENTinel 1.1 performance, both in the overall score and on each subtest, within each broad classification of quantitative and qualitative OD. For example, a larger than expected percent of participants in the quantitative OD group accurately detected the odor on the SCENTinel 1.1 test, which may reflect the quantitative OD group predominantly having hyposmia (84/135 = 62%; Figure 4). Despite the heterogeneity, the overall score and subtests of

SCENTinel 1.1 still accurately discriminated between normosmia, quantitative OD, and qualitative OD groups with acceptable sensitivity (AUC > 0.7).

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

To reduce the heterogeneity, when we assessed how well individual smell groups performed on SCENTinel 1.1, we found that SCENTinel 1.1 can discriminate between those with anosmia, hyposmia, and parosmia. Despite the smaller sample size, SCENTinel 1.1 was more sensitive at discriminating between anosmia, hyposmia, and parosmia groups than the broad quantitative and qualitative OD group classifications, likely because the individual smell groups are less heterogeneous classifications. Phantosmia was not included because of the limited sample size (N = 9). More research is needed to understand how those with phantosmia perform on SCENTinel. Different SCENTinel 1.1 subtests were able to discriminate between different groups. There was no difference in odor detection, but odor intensity was able to discriminate anosmia from hyposmia, and parosmia. Odor identification and the hedonic score discriminated between hyposmia and parosmia. The present study highlights the complexity of classifying individual olfactory disorders, both quantitative and qualitative alike, with a rapid, self-administered smell test. While we only included individuals with a single olfactory disorder in our analyses, individuals can have a quantitative and qualitative olfactory disorder simultaneously (e.g., hyposmia and parosmia), and it is rare to have a single qualitative olfactory disorder alone [3]. One area of future research is to explore these complexities to better classify olfactory disorders using SCENTinel. The SCENTinel 1.1 overall score consistently discriminated between groups at rates significantly better than chance, with a similar or higher accuracy than any subtest. Many other smell tests only use one olfactory function (e.g., summed performance from odor identification)

to classify olfactory disorders [19,28]. However, our results show that while incorrectly

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

identifying an odor indicates that someone has an olfactory disorder, more information is needed to determine whether the nature of such disorder is quantitative (indicating olfactory loss) or qualitative (indicating olfactory distortions). Assessing odor detection, intensity, identification, and hedonic score within the SCENTinel 1.1 test provides information about participants' olfactory abilities beyond the usually tested olfactory identification. Measuring different olfactory functions reveals response patterns commonly associated with different etiologies of olfactory disorders [54]. For example, in a group of individuals with hyposmia from various etiologies who completed the Sniffin' Sticks extended test battery (completion time ~45 mins), those with hyposmia from Parkinson's disease performed well on odor threshold tests, but had reduced odor detection and identification ability, likely because of impaired central olfactory information processing. Those with hyposmia from sinonasal disease performed well on odor detection and identification, but had poor olfactory thresholds, likely because of anatomical obstruction, or inflammation and edema [54]. To the best of our knowledge, SCENTinel 1.1 is the only tool that can screen for multiple olfactory functions in less than 5 minutes, and that has the potential to provide etiological insight. Including the hedonic score in SCENTinel 1.1 was successful in discriminating parosmia. As hypothesized, participants with parosmia reported a lower hedonic score compared to participants without parosmia, driven by a lower hedonic rating of the target odor on the SCENTinel card, as the hedonic rating of the imagined vomit odor was not different between participants with and without parosmia. This finding supports reports of individuals with parosmia often finding odors to be unpleasant [39]. However, less commonly, some patient reports have shown a valence flip - in addition to pleasant odors smelling unpleasant, reporting odors typically experienced as foul are now pleasant [31,55,56]. To test this valence flip theory,

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

an actual unpleasant target odor may need to be experienced to capture the less-common negative-to-positive hedonic experience, as our use of an imagined unpleasant odor was not adequate. Furthermore, specific distortions have been reported, coffee being prominently reported in interviews with patients who have parosmia [2,40]. However, we did not find any significant difference in hedonic scores between the flower, coffee, bubblegum, or caramel popcorn odors used in SCENTinel 1.1. Notably, we did not assess individual parosmia triggers in the participants with parosmia, therefore it is unknown if coffee was a specific odor distortion in our current sample. Someone with parosmia may still be able to guess the identity of an odor if they know what their distortion is triggered by (for example, if coffee typically smells like gasoline, and they smell gasoline on the smell test, they might accurately identify the odor as coffee because of the association). Therefore, a hedonic score that assesses pleasantness circumvents this issue of accurately identifying odors that are known distortions. Overall, our findings partially support the rationale to use the hedonic score proposed by Liu et al [27], capturing positive odors smelling negative. More research is needed to account for the impact of varying etiologies of olfactory disorders. Presently, SCENTinel 1.1 accurately predicted group classification in participants who experienced olfactory disorders because of COVID-19, which supports the use of SCENTinel 1.1 to understand COVID-19 olfactory symptoms. It also supports the use of SCENTinel 1.1 as a tool to help detect and monitor sudden loss of smell, which is a symptom of COVID-19 [5,57], as well as parosmia, an evolving symptom of COVID-19 [31,36,37]. Early diagnosis of olfactory impairment is critical for establishing successful outcomes to treatment regimens like olfactory training [58] which has recently shown effectiveness with patients with parosmia [59].

Limitations

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

Participants were grouped based on their self-reported olfactory disorders. It is possible that participants did not accurately classify their olfactory disorder [7,60]. To limit inaccurate data, we asked specific questions describing their smell loss (Figure 4) and excluded participants whose self-reported olfactory disorder did not fit conventional categories (i.e. someone who reported having both anosmia and hyposmia). An area of future research is to directly screen for smell function with another validated smell test to better understand how they perform on SCENTinel. Granted, there are no direct, validated tests that diagnose parosmia aside from SCENTinel 1.1. Until then, in-depth interviews would be necessary. Another limitation of this study is that COVID-19 test results were also self-reported. However, participants in this study were recruited from a Facebook group specifically for those with smell loss from COVID-19, and specific questions describing the cause of their smell loss (In your opinion, what might have been the cause of your smell loss? Selected "COVID-19"), and their COVID-19 test results [What was the test result? 1) Selected "Positive Lab Test (COVID+)"] were included to eliminate participants who had smell loss unrelated to COVID-19 and reduce heterogeneity. Nevertheless, SCENTinel 1.1 was designed to test for olfactory disorders regardless of the etiology; thus, inaccurate reports of COVID-19 diagnosis are not expected to alter the results. However, this is another area where future studies are needed. Finally, SCENTinel 1.1 uses one of four different odors in each test. Including more odor options, particularly unpleasant odors, may help to better measure and understand parosmia. Not all odors are equally distorted in those who experience parosmia [40]. The four odors used in SCENTinel 1.1 may not have been odors that were distorted in the participants with parosmia.

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

Conclusion Screening for various olfactory disorders is complex and due to the heterogeneity between and within olfactory disorders, often takes time and specialty expertise. Despite being a rapid, inexpensive, self-administered test, SCENTinel 1.1 can discriminate between those with selfreported normosmia and quantitative (i.e., anosmia or hyposmia), and qualitative (i.e., parosmia and/or phantosmia) olfactory disorders with a high degree of accuracy. By assessing hedonics, SCENTinel is a direct smell test that can rapidly capture self-reported parosmia. SCENTinel may serve as a useful tool in research settings to assess smell function. **Competing interests** On behalf of the authors of this manuscript, the Monell Chemical Senses Center and Temple University have been awarded patent protection (US patent no 11,337,640) and this patent has been licensed to Ahersla Health, Inc. The authors may benefit financially through their institution's patent policy. **Author contributions** SRH: manuscript writing and reviewing; MEH: conceptualization, pre-registration, data collection, data analysis, manuscript writing and reviewing; RP: data analysis, manuscript writing and reviewing; MAO: conceptualization, revision; NER: revision; DRR: conceptualization, revision; PHD: conceptualization, revision; VP: conceptualization, preregistration, revision.

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

Funding We acknowledge support from the National Institutes of Health as part of the RADx-rad initiative (U01 DC019578 to PHD and VP). MEH was supported by NIH T32 (DC000014) and F32 (DC020100) funding during this work; RP was supported by NIH T32 funding (DC000014) and F32 (DC020380). Acknowledgments This work would not be possible without people who are willing to participate in the research. We are extremely grateful to Chrissi Kelly for bridging researchers and the community of patients with smell loss through the UK-based charity AbScent. With her gracious support, we were able to recruit from AbScent's social media pages. We also wholeheartedly thank the participants - people living with olfactory disorders and allies - for their contribution to the development of SCENTinel, a tool that we hope to put at the service of the whole population. **Data Availability** The data and analysis script will be publicly available on OSF upon acceptance of the publication [48].

References

- 1. Rawal S, Hoffman HJ, Bainbridge KE, Huedo-Medina TB, Duffy VB. Prevalence and
- risk factors of self-reported smell and taste alterations: results from the 2011-2012 US national
- health and nutrition examination survey (NHANES). Chem Senses. 2016 Jan;41(1):69–76.
- 546 2. Bonfils P, Avan P, Faulcon P, Malinvaud D. Distorted odorant perception: analysis of a
- series of 56 patients with parosmia. Arch Otolaryngol Head Neck Surg. 2005 Feb;131(2):107–
- 548 12.

- Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, et al.
- Position paper on olfactory dysfunction. Rhinology. 2016 Jan 31;56(1):1–30.
- 551 4. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life--an updated review.
- 552 Chem Senses. 2014 Mar;39(3):185–94.
- 553 5. Gerkin RC, Ohla K, Veldhuizen MG, Joseph PV, Kelly CE, Bakke AJ, et al. Recent
- smell loss is the best predictor of COVID-19 among individuals with recent respiratory
- symptoms. Chem Senses [Internet]. 2020 Dec 25 [cited 2021 Feb 11];(bjaa081). Available from:
- https://doi.org/10.1093/chemse/bjaa081
- 557 6. CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. [cited
- 558 2022 June 28]. Available from: https://covid.cdc.gov/covid-data-tracker/#datatracker-home
- 559 7. Hannum ME, Ramirez VA, Lipson SJ, Herriman RD, Toskala AK, Lin C, et al. Objective
- sensory testing methods reveal a higher prevalence of olfactory loss in COVID-19–positive
- patients compared to subjective methods: a systematic review and meta-analysis. Chem Senses.
- 562 2020 Nov 1;45(9):865–74.
- 563 8. Chiesa-Estomba CM, Lechien JR, Radulesco T, Michel J, Sowerby LJ, Hopkins C, et al.
- Patterns of smell recovery in 751 patients affected by the COVID-19 outbreak. Eur J Neurol.
- 565 2020/08/05 ed. 2020 Nov;27(11):2318–21.
- 566 9. Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose
- throat-related symptoms with a focus on loss of smell and/or taste in COVID-19 patients. Am J
- 568 Otolaryngol. 2020/06/23 ed. 2020;41(6):102622–102622.
- 569 10. Vaira LA, Hopkins C, Petrocelli M, Lechien JR, Chiesa-Estomba CM, Salzano G, et al.
- 570 Smell and taste recovery in coronavirus disease 2019 patients: a 60-day objective and
- prospective study. J Laryngol Otol. 2020 Aug;134(8):703–9.
- 572 11. Reiter ER, Coelho DH, Kons ZA, Costanzo RM. Subjective smell and taste changes
- 573 during the COVID-19 pandemic: Short term recovery. Am J Otolaryngol. 2020
- 574 Dec;41(6):102639.
- 575 12. Moein ST, Hashemian SM, Tabarsi P, Doty RL. Prevalence and reversibility of smell
- dysfunction measured psychophysically in a cohort of COVID-19 patients. Int Forum Allergy
- 577 Rhinol. 2020 Oct;10(10):1127–35.
- 578 13. Vihta K-D, Pouwels KB, Peto TE, Pritchard E, House T, Studley R, et al. Omicron-
- associated changes in SARS-COV-2 symptoms in the United Kingdom. Medrxiv. 2022 Jan
- 580 1;2022.01.18.22269082.
- 581 14. Ben Killingley, Alex Mann, Mariya Kalinova, Alison Boyers, Niluka Goonawardane, Jie
- Zhou, et al. Safety, tolerability, and viral kinetics during SARS-cov-2 human challenge. Nat
- 583 Portf [Internet]. 2022 Feb 28; Available from: https://doi.org/10.21203/rs.3.rs-1121993/v1
- 584 15. Oleszkiewicz A, Kunkel F, Larsson M, Hummel T. Consequences of undetected
- olfactory loss for human chemosensory communication and well-being. Philos Trans R Soc
- 586 Lond B Biol Sci. 2020 Jun 8;375(1800):20190265.

- 587 16. Rawal S, Hoffman HJ, Honda M, Huedo-Medina TB, Duffy VB. The Taste and Smell
- Protocol in the 2011–2014 US National Health and Nutrition Examination Survey (NHANES):
- test-retest reliability and validity testing. Chemosens Percept. 2015 Sep;8(3):138–48.
- 590 17. Dalton P, Hummel T. Chemosensory function and response in idiopathic environmental
- intolerance. Occup Med Phila Pa. 2000 Sep;15(3):539–56.
- 592 18. Lötsch J, Hummel T. A machine-learned analysis suggests non-redundant diagnostic
- information in olfactory subtests. IBRO Rep. 2019 Jun;6:64–73.
- 594 19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell
- 595 Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav.
- 596 1984 Mar;32(3):489–502.
- 597 20. Doty RL, Marcus A, Lee WW. Development of the 12-Item Cross-Cultural Smell
- Identification Test(CC-SIT). The Laryngoscope. 1996;106(3):353–6.
- 599 21. Kondo H, Matsuda T, Hashiba M, Baba S. A study of the relationship between the T&T
- olfactometer and the University of Pennsylvania Smell Identification Test in a Japanese
- 601 population. Am J Rhinol. 1998 Oct;12(5):353–8.
- Duff K, mccaffrey RJ, Solomon GS. The Pocket Smell Test. J Neuropsychiatry Clin
- 603 Neurosci. 2002 May 1;14(2):197–201.
- 604 23. Choudhury ES, Moberg P, Doty RL. Influences of age and sex on a microencapsulated
- odor memory test. Chem Senses. 2003 Nov 1;28(9):799–805.
- 506 24. Jackman AH, Doty RL. Utility of a three-item smell identification test in detecting
- olfactory dysfunction. The Laryngoscope. 2005 Dec;115(12):2209–12.
- 608 25. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': Olfactory
- performance assessed by the combined testing of odor identification, odor discrimination and
- olfactory threshold. Chem Senses. 1997 Feb 1;22(1):39–52.
- 611 26. Croy I, Zehner C, Larsson M, Zucco GM, Hummel T. Test-retest reliability and validity
- of the Sniffin' TOM Odor Memory Test. Chem Senses. 2015 Mar 1;40(3):173–9.
- 613 27. Liu DT, Welge-Lüssen A, Besser G, Mueller CA, Renner B. Assessment of odor hedonic
- perception: the Sniffin' sticks parosmia test (ssparot). Sci Rep. 2020 Oct 22;10(1):18019.
- Dalton P, Doty RL, Murphy C, Frank R, Hoffman HJ, Maute C, et al. Olfactory
- assessment using the NIH Toolbox. Neurology. 2013 Mar 12;80(Issue 11, Supplement 3):S32–6.
- 617 29. Parma V, Hannum ME, O'Leary M, Pellegrino R, Rawson NE, Reed DR, et al.
- 618 SCENTinel 1.0: development of a rapid test to screen for smell loss. Chem Senses. 2021 Mar 27;
- 619 30. Landis BN, Frasnelli J, Croy I, Hummel T. Evaluating the clinical usefulness of
- structured questions in parosmia assessment. The Laryngoscope. 2010 Aug;120(8):1707–13.
- 621 31. Pellegrino R, Mainland JD, Kelly CE, Parker JK, Hummel T. Prevalence and correlates
- of parosmia and phantosmia among smell disorders. Chem Senses. 2021 Jan 1;46:bjab046.
- 623 32. Nordin S, Brämerson A, Millqvist E, Bende M. Prevalence of parosmia: the Skövde
- 624 population-based studies. Rhinology. 2007 Mar;45(1):50–3.
- 625 33. Leopold D. Distortion of olfactory perception: diagnosis and treatment. Chem Senses.
- 626 2002 Sep;27(7):611–5.
- 627 34. Frasnelli J, Landis BN, Heilmann S, Hauswald B, Hüttenbrink KB, Lacroix JS, et al.
- 628 Clinical presentation of qualitative olfactory dysfunction. Eur Arch Oto-Rhino-Laryngol Off J
- 629 Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol Head Neck Surg.
- 630 2004 Aug;261(7):411–5.
- 631 35. Keller A, Malaspina D. Hidden consequences of olfactory dysfunction: a patient report
- series. BMC Ear Nose Throat Disord. 2013 Jul 23:13:8.

- 633 36. Ohla K, Veldhuizen MG, Green T, Hannum ME, Bakke AJ, Moein ST, et al. Increasing
- incidence of parosmia and phantosmia in patients recovering from COVID-19 smell loss.
- 635 Medrxiv. 2021 Jan 1;2021.08.28.21262763.
- 636 37. Tognetti A, Thunell E, Olsson MJ, Greilert N, Havervall S, Thålin C, et al. High
- prevalence of olfactory disorders 18 months after contracting COVID-19. Medrxiv. 2022 Jan
- 638 1;2022.01.20.22269490.
- 639 38. Said M, Luong T, Jang SS, Davis ME, deconde AS, Yan CH. Clinical factors associated
- with lower health scores in COVID-19-related persistent olfactory dysfunction. Int Forum
- Allergy Rhinol [Internet]. 2022 Jan 15 [cited 2022 Feb 4];n/a(n/a). Available from:
- 642 https://doi.org/10.1002/alr.22978
- 643 39. Deems DA, Doty RL, Settle RG, Moore-Gillon V, Shaman P, Mester AF, et al. Smell and
- taste disorders, a study of 750 patients from the University of Pennsylvania Smell and Taste
- 645 Center. Arch Otolaryngol Neck Surg. 1991 May 1;117(5):519–28.
- 646 40. Parker JK, Kelly CE, Smith B, Hopkins C, Gane SB. An analysis of patients'
- perspectives on qualitative olfactory dysfunction using social media. JMIR Form Res. 2021;
- 648 41. Callahan CD, Hinkebein JH. Assessment of anosmia after traumatic brain injury:
- performance characteristics of the University of Pennsylvania Smell Identification Test. J Head
- 650 Trauma Rehabil. 2002 Jun;17(3):251–6.
- 651 42. Callahan CD, Hinkebein J. Neuropsychological significance of anosmia following
- traumatic brain injury. J Head Trauma Rehabil. 1999 Dec;14(6):581–7.
- 653 43. Bratt M, Skandsen T, Hummel T, Moen KG, Vik A, Nordgård S, et al. Frequency and
- prognostic factors of olfactory dysfunction after traumatic brain injury. Brain Inj.
- 655 2018;32(8):1021–7.
- 656 44. Albers MW, Tabert MH, Devanand DP. Olfactory dysfunction as a predictor of
- 657 neurodegenerative disease. Curr Neurol Neurosci Rep. 2006 Sep;6(5):379–86.
- 658 45. Barresi M, Ciurleo R, Giacoppo S, Foti Cuzzola V, Celi D, Bramanti P, et al. Evaluation
- of olfactory dysfunction in neurodegenerative diseases. J Neurol Sci. 2012 Dec 15;323(1–2):16–
- 660 24.
- 661 46. Dintica CS, Marseglia A, Rizzuto D, Wang R, Seubert J, Arfanakis K, et al. Impaired
- olfaction is associated with cognitive decline and neurodegeneration in the brain. Neurology.
- 663 2019 Feb 12:92(7):e700–9.
- Lee DY, Lee WH, Wee JH, Kim J-W. Prognosis of postviral olfactory loss: follow-up
- study for longer than one year. Am J Rhinol Allergy. 2014 Sep 1;28(5):419–22.
- 48. Hannum M, Parma V, Pellegrino R, Dalton P, Reed D. Distinguishing qualitative smell
- disorders from quantitative using the SCENTinel test. 2021 Jan 21 [cited 2021 Mar 18];
- Available from: https://osf.io/twu4e
- 669 49. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The redcap
- 670 consortium: building an international community of software platform partners. J Biomed
- 671 Inform. 2019 Jul 1;95:103208.
- 672 50. Ruopp, M. D., Perkins, N. J., Whitcomb, B. W. & Schisterman, E. F. Youden Index and
- optimal cut-point estimated from observations affected by a lower limit of detection. *Biom. J.*
- 674 *Biom. Z.* **50**, 419–430 (2008).
- 675 51. Hsieh, J. W., Keller, A., Wong, M., Jiang, R.-S. & Vosshall, L. B. SMELL-S and
- 676 SMELL-R: Olfactory tests not influenced by odor-specific insensitivity or prior olfactory
- 677 experience. Proc. Natl. Acad. Sci. U. S. A. 114, 11275–11284 (2017).

- 52. Schönbrodt FD, Zehetleitner M, Wagenmakers E-J, Perugini M. Sequential hypothesis
- testing with Bayes factors: efficiently testing mean differences. Psychol Methods.
- 680 2017;22(2):322–39.
- 681 53. R Core T. R: A language and environment for statistical computing. 2021;
- 682 54. Whitcroft KL, Cuevas M, Haehner A, Hummel T. Patterns of olfactory impairment
- reflect underlying disease etiology. The Laryngoscope. 2017 Feb;127(2):291–5.
- 684 55. Parker JK, Kelly CE, Gane SB. Molecular mechanism of parosmia [Internet].
- Otolaryngology; 2021 Feb [cited 2021 May 13]. Available from:
- 686 http://medrxiv.org/lookup/doi/10.1101/2021.02.05.21251085
- 687 56. Landis BN, Frasnelli J, Hummel T. Euosmia: A rare form of parosmia. Acta Otolaryngol
- 688 (Stockh). 2006 Jan 1;126(1):101–3.
- 689 57. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time
- tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020 Jul
- 691 1;26(7):1037–40.
- 692 58. Kattar N, Do TM, Unis GD, Migneron MR, Thomas AJ, mccoul ED. Olfactory training
- 693 for postviral olfactory dysfunction: systematic review and meta-analysis. Otolaryngol--Head
- Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg. 2021 Feb;164(2):244–54.
- 695 59. Aldundag A, Yilmaz E, Kesimli MC. Modified olfactory training is an effective
- treatment method for COVID-19 induced parosmia. The Laryngoscope [Internet]. 2022 Mar 7
- 697 [cited 2022 Mar 15];n/a(n/a). Available from: https://doi.org/10.1002/lary.30101
- 698 60. Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Hans S, Calvo-Henriquez C,
- et al. Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-
- 700 19 patients. Head Neck. 2020 Jul;42(7):1583–90.

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

Figure Captions Figure 1. Validation of the original SCENTinel 1.0 classification model. SCENTinel 1.1discriminated anosmia and normosmia in a COVID-19-related population (teal color; n = 51 with anosmia, 66 with normosmia) were well fitted to the original SCENTinel 1.0 classification model. Melon color refers to the model performance of SCENTinel 1.0 with the original sample (n = 111 with anosmia, 154 with normosmia). False positive and true positive rates corresponds to the performance of the classification model to accurately predict an individual as someone with 'anosmia' or someone with 'normosmia' based on their SCENTinel results. Figure 2. Receiver operating characteristic (ROC) curves and statistics on SCENTinel 1.1 scores overall and for single subtests across groups based on the linear discriminant analysis algorithm: (A) individuals with normosmia (n = 66) versus quantitative dysfunction (n = 135); (B) individuals with quantitative dysfunction versus qualitative dysfunction (n = 86); (C) individuals with normosmia versus qualitative dysfunction. Quantitative dysfunction encompasses individuals with anosmia or hyposmia; qualitative dysfunction includes individuals with parosmia and/or phantosmia. Intensity and hedonics are continuous. AUC, area under the curve; p, p-value; D, DeLong's test for 2 ROC curves; df, degrees of freedom. **Figure 3.** Investigation of the hedonic score across individuals with or without parosmia. A) Comparison of average hedonic score across individual smell groups (n = 84 with hyposmia, 66 with normosmia, 66 with parosmia). B) Relationship between hedonic score and frequency of parosmia events (determined via participant's response to "How often have you experienced

smells being distorted or don't smell like they used to?"; n = 66). C) Comparison of average hedonic score per odor across those with and without parosmia (n = 150 without parosmia, 66 with parosmia). D) Comparison of average hedonic rating and vomit rating across those with and without parosmia. Errors bars indicate standard deviation.

Figure 4. Summary of participants in the current study. Final smell group classifications (quantitative, qualitative, mixed, and normosmia) were based on the self-report answers to the question stated. Quantitative smell disorders are classified as those with a change in the perceived intensity of odors. Qualitative smell disorders include those where the perceptual quality or identity of an odor has changed. Thick-lined and dashed boxes are used in the final analyses.




Figure 1. Validation of the original SCENTinel 1.0 classification model. SCENTinel 1.1-discriminated anosmia and normosmia in a COVID-19-related population (teal color; n = 51 with anosmia, 66 with normosmia) were well fitted to the original SCENTinel 1.0 classification model. Melon color refers to the model performance of SCENTinel 1.0 with the original sample (n = 111 with anosmia, 154 with normosmia). False positive and true positive rates corresponds to the performance of the classification model to accurately predict an individual as someone with 'anosmia' or someone with 'normosmia' based on their SCENTinel results.




Figure 2. Receiver operating characteristic (ROC) curves and statistics on SCENTinel 1.1 scores overall and for single subtests across groups based on the linear discriminant analysis algorithm: (A) individuals with normosmia (n = 66) versus quantitative dysfunction (n = 135); (B) individuals with quantitative dysfunction versus qualitative dysfunction (n = 86); (C) individuals with normosmia versus qualitative dysfunction. Quantitative dysfunction encompasses individuals with anosmia or hyposmia; qualitative dysfunction includes individuals with parosmia and/or phantosmia. Intensity and hedonics are continuous. AUC, area under the curve; p, p-value; D, DeLong's test for 2 ROC curves; df, degrees of freedom.




Figure 3. Investigation of the hedonic score across individuals with or without parosmia. A) Comparison of average hedonic score across individual smell groups (N=84 with hyposmia, 66 with normosmia, 66 with parosmia). B) Relationship between hedonic score and frequency of parosmia events (determined via participant's response to "How often have you experienced smells being distorted or don't smell like they used to?"; N=66). C) Comparison of average hedonic score per odor across those with and without parosmia (N=150 without parosmia, 66 with parosmia). D) Comparison of average hedonic rating and vomit rating across those with and without parosmia. Error bars indicate standard deviation.




Figure 4. Summary of participants in the current study. Final smell group classifications (quantitative, qualitative, mixed, and normosmia) were based on the self-report answers to the question stated. Quantitative smell disorders are classified as those with a change in the perceived intensity of odors. Qualitative smell disorders include those where the perceptual quality or identity of an odor has changed. Thick-lined and dashed boxes are used in the final analyses.

Table 1. SCENTinel 1.1 accuracy matrix: potential response patterns that determine overall score classification of correct/incorrect.

Response Pattern #	Odor Detection	Odor Intensity (range 1-100)	Odor Identification		Overall
			First attempt	Second attempt	Score
1	Correct	≥ 21	Correct	NA	Correct
2	Correct	≤ 20	Correct	NA	Incorrect
3	Correct	≥ 21	Incorrect	Correct	Correct
4	Correct	≤ 20	Incorrect	Correct	Incorrect
5	Correct	≥ 21	Incorrect	Incorrect	Correct
6	Correct	≤ 20	Incorrect	Incorrect	Incorrect
7	Incorrect	≥ 21	Correct	NA	Correct
8	Incorrect	≤ 20	Correct	NA	Incorrect
9	Incorrect	≥ 21	Incorrect	Correct	Incorrect
10	Incorrect	≤ 20	Incorrect	Correct	Incorrect
11	Incorrect	≥ 21	Incorrect	Incorrect	Incorrect
12	Incorrect	≤ 20	Incorrect	Incorrect	Incorrect

Note: # = response pattern number. Odor detection is by a triangle test. "First attempt" is a four-alternative forced-choice. "Second attempt" is a three-alternative forced choice.

